Bevacizumab loaded solid lipid nanoparticles prepared by the coacervation technique: Preliminary in vitro studies

Nanotechnology

Volumn 26, Issue 25, 2015, Pages

  Battaglia, Luigi ^a   Gallarate, Marina ^a   Peira, Elena ^a   Chirio, Daniela ^a   Solazzi, Ilaria ^a   Giordano, Susanna Marzia Adele ^a   Gigliotti, Casimiro Luca ^b   Riganti, Chiara ^c   Dianzani, Chiara ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

anti VEGF; BBB; bevacizumab; coacervation; HUVEC; ion pair; solid lipid nanoparticles

Indexed keywords

BLOOD; BRAIN; CELLS; DIAGNOSIS; DRUG PRODUCTS; FATTY ACIDS; NANOPARTICLES; TUMORS;

ANTI-VEGF; BBB; BEVACIZUMAB; COACERVATION; HUVEC; ION PAIRS; SOLID LIPID NANOPARTICLE (SLN);

PATIENT TREATMENT;

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; DRUG CARRIER; FATTY ACID; NANOPARTICLE;

CELL CULTURE; CHEMICAL PHENOMENA; CHEMISTRY; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; PARTICLE SIZE; PERMEABILITY; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; CELLS, CULTURED; DRUG CARRIERS; FATTY ACIDS; GLIOBLASTOMA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IN VITRO TECHNIQUES; NANOPARTICLES; PARTICLE SIZE; PERMEABILITY;

EID: 84931275028     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/26/25/255102     Document Type: Article

References (33)

1. Seystahl K and Weller M 2012 Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma? Expert Opin. Investig. Drugs 21 605-17
2. Patel M, Vogelbaum M A, Barnett G H, Jalali R and Ahluwalia M S 2012 Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions Expert Opin. Investig. Drugs 21 1247-66
3. Sathornsumetee S, Reardon D A, Desjardins A, Quinn J A, Vredenburgh J J and Rich J N 2007 Molecularly targeted therapy for malignant glioma Cancer 110 13-24
4. Rahmathulla G, Hovey E J, Hashemi-Sadraei N and Ahluwalia M S 2013 Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges Onco. Targ. Ther. 6 371-89
5. Narita Y 2013 Drug review: safety and efficacy of bevacizumab for glioblastoma and other brain tumors Japan. J. Clin. Oncol. 43 587-95
6. Jakobsen J N, Hasselbalch B, Stockhausen M T, Lassen U and Skovgaard Poulsen H 2011 Irinotecan and bevacizumab in recurrent glioblastoma multiforme Expert Opin. Pharmacother. 12 825-33
7. Ulbrich K, Knobloch T and Kreuter J 2011 Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB) J. Drug Target 19 125-32
8. Hau P et al 2004 Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma Cancer 100 1199-207
9. Deeken J F and Loscher W 2007 The blood-brain barrier and cancer: transporters, treatment, and Trojan horses Clin. Cancer Res. 13 1663-74
10. Dallas S, Miller D S and Bendayan R 2006 Multidrug resistance-associated proteins: expression and function in the central nervous system Pharmacol. Rev. 58 140-61
11. Barbu E, Molnàr E, Tsibouklis J and Górecki D C 2009 The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier Expert Opin. Drug Deliv. 6 553-65
12. Müller R H, Mäder K and Gohla S 2000 Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art Eur. Pharm. Biopharm. 50 161-77
13. Wong H L, Bendayan R, Rauth A M, Li Y and Wu X Y 2007 Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles Adv. Drug Deliver Rev. 59 491-504
14. Hong Y, Jing M, Yong-Zhong D, Jian Y, Fu-Qiang H and Su Z 2008 Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells Int. J. Pharm. 348 137-45
15. Teskac K and Kristl J 2010 The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol Int. J. Pharm. 390 61-9
16. Battaglia L, Gallarate M, Cavalli R and Trotta M 2010 Solid lipid nanoparticles produced through a coacervation method J. Microencaps. 27 78-85
17. Battaglia L and Gallarate M 2012 Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery Expert Opin. Drug Deliv. 9 497-508
18. Gallarate M, Trotta M, Battaglia L, Chirio D and Cisplatin-loaded S L N 2010 Produced by coacervation technique J. Drug Del. Sci. Tech. 20 1561-73
19. Gallarate M, Battaglia L, Peira E and Trotta M 2011 Peptide-loaded solid lipid nanoparticles prepared through coacervation technique Int. J. Chem. Eng. 132435
20. Battaglia L, Serpe L, Muntoni E, Zara G P, Trotta M and Gallarate M 2011 Methotrexate loaded SLNs prepared by coacervation technique: in vitro cytotoxicity and in vivo pharmacokinetics and biodistribution Nanomedicine (London) 6 1561-73
21. Battaglia L et al 2014 SLN for potential delivery in glioblastoma treatment: preliminary in vitro studies J. Pharm. Sci. 103 2157-65
22. Chirio D et al 2014 Positive-charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma treatment Eur. J. Pharm. Biopharm. 88 746-58
23. Dolo V Biocidal composition PCT Patent Specification WO2013/127568 A1
24. Aitken A and Learmonth M P 2002 Protein determination by UV absorption The Protein Protocol Handbook (New York: Humana Press) pp 3-6
25. Pescina S, Ferrari G, Govoni P, Macaluso C, Padula C, Santi P and Nicoli S 2010 In-vitro permeation of bevacizumab through human sclera: effect of iontophoresis application J. Pharm. Pharmacol. 62 1189-94
26. Wood B T, Thompson S H and Goldstein G 1965 Fluorescent antibody staining. 3. Preparation of fluorescein-isothiocyanate-labeled antibodies J. Immunol. 95 225-9
27. Weksler B B et al 2005 Blood-brain barrier-specific properties of a human adult brain endothelial cell line FASEB J. 19 1872-4
28. Siflinger-Birnboim A, Del Vecchio P J, Cooper J A, Blumenstock F A, Shepard J M and Malik A B 1987 Molecular sieving characteristics of the cultured endothelial monolayer J. Cell Physiol. 132 111-7
29. Riganti C et al 2014 Temozolomide down-regulates P-glycoprotein in human blood-brain barrier cells by disrupting Wnt3-signalling Cell Mol. Life Sci. 71 499-516
30. Ferrara N, Hillan K J, Gerber H P and Novotny W 2004 Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat. Rev. Drug Discovery 3 391-400
31. Stevenson C E, Nagahashi M, Ramachandran S, Yamada A, Bear H D and Takabe K 2012 Bevacizumab and breast cancer: what does the future hold? Future Oncol. 8 403-14
32. Agarwal S, Sane R, Oberoi R, Ohlfest J R and Elmquis W F 2011 Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain Expert Rev. Mol. Med. 13 e17 13
33. Tai L M, Loughlin A J, Male D K and Romero I A 2009 P-glycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid J. Cereb. Blood Flow Metab. 29 1079-83